The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen.

Ad26.ZEBOV Ebola MVA-BN-Filo immunogenicity malaria vaccine

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
02 Aug 2023
Historique:
received: 01 07 2023
revised: 26 07 2023
accepted: 28 07 2023
medline: 26 8 2023
pubmed: 26 8 2023
entrez: 26 8 2023
Statut: epublish

Résumé

We assessed whether the immunogenicity of the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen with a 56-day interval between doses was affected by exposure to malaria before dose 1 vaccination and by clinical episodes of malaria in the period immediately after dose 1 and after dose 2 vaccinations. Previous malaria exposure in participants in an Ebola vaccine trial in Sierra Leone (ClinicalTrials.gov: NCT02509494) was classified as low, intermediate, and high according to their antibody responses to a panel of

Identifiants

pubmed: 37631885
pii: vaccines11081317
doi: 10.3390/vaccines11081317
pmc: PMC10459393
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02509494']

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Medical Research Council
ID : MR/S03286X/1
Pays : United Kingdom

Références

Clin Infect Dis. 2022 Oct 29;75(9):1585-1593
pubmed: 35640636
J Infect Dis. 2021 Dec 1;224(11):1907-1915
pubmed: 34013349
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
Lancet Infect Dis. 2022 Jan;22(1):97-109
pubmed: 34529963
Elife. 2015 May 08;4:
pubmed: 25955968
Ann Trop Med Parasitol. 1985 Dec;79(6):563-73
pubmed: 3834841
Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4438-47
pubmed: 26216993
Pediatr Infect Dis J. 2000 May;19(5):444-9
pubmed: 10819341
Nat Commun. 2019 Oct 15;10(1):4531
pubmed: 31615986
Lancet. 2015 Aug 29;386(9996):857-66
pubmed: 26248676
Antiviral Res. 2018 Nov;159:63-67
pubmed: 30261226
Lancet. 2019 Nov 23;394(10212):1893
pubmed: 31777382
J Infect Dev Ctries. 2015 Feb 19;9(2):197-205
pubmed: 25699495
Emerg Infect Dis. 2022 Mar;28(3):734-738
pubmed: 35202536
Clin Infect Dis. 2020 Jun 10;70(12):2544-2552
pubmed: 31402382
PLoS One. 2022 Jul 6;17(7):e0270968
pubmed: 35793331

Auteurs

Daniela Manno (D)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

Catriona Patterson (C)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

Abdoulie Drammeh (A)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.

Kevin Tetteh (K)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

Mattu Tehtor Kroma (MT)

EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.
College of Medicine and Allied Health Sciences, University of Sierra Leone, New England Ville, Freetown, Sierra Leone.

Godfrey Tuda Otieno (GT)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.

Bolarinde Joseph Lawal (BJ)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.

Seyi Soremekun (S)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

Philip Ayieko (P)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza P.O. Box 11936, Tanzania.

Auguste Gaddah (A)

Janssen Research and Development, 2340 Beerse, Belgium.

Abu Bakarr Kamara (AB)

EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.
College of Medicine and Allied Health Sciences, University of Sierra Leone, New England Ville, Freetown, Sierra Leone.

Frank Baiden (F)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.

Muhammed Olanrewaju Afolabi (MO)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.

Daniel Tindanbil (D)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.

Kwabena Owusu-Kyei (K)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.

David Ishola (D)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.

Gibrilla Fadlu Deen (GF)

College of Medicine and Allied Health Sciences, University of Sierra Leone, New England Ville, Freetown, Sierra Leone.

Babajide Keshinro (B)

Janssen Vaccines and Prevention, 2333 CB Leiden, The Netherlands.

Yusupha Njie (Y)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.

Mohamed Samai (M)

College of Medicine and Allied Health Sciences, University of Sierra Leone, New England Ville, Freetown, Sierra Leone.

Brett Lowe (B)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
KEMRI-Wellcome Trust Research Programme, Kilifi P.O. Box 230, Kenya.

Cynthia Robinson (C)

Janssen Vaccines and Prevention, 2333 CB Leiden, The Netherlands.

Bailah Leigh (B)

College of Medicine and Allied Health Sciences, University of Sierra Leone, New England Ville, Freetown, Sierra Leone.

Chris Drakeley (C)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

Brian Greenwood (B)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

Deborah Watson-Jones (D)

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza P.O. Box 11936, Tanzania.

Classifications MeSH